Catalog No. size PriceQuantity
M7103-2 2mg solid $107
M7103-10 10mg solid $441


AB928 is a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy

Product information

CAS Number: 2239273-34-6

Molecular Weight: 426.47

Formula: C23H22N8O




AB 928

Chemical Name: 3-[2-Amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile

Smiles: CC1C(=CC=CC=1C1=CC(=NC(N)=N1)C1=CN(CC2=CC=CC(=N2)C(C)(C)O)N=N1)C#N


InChi: InChI=1S/C23H22N8O/c1-14-15(11-24)6-4-8-17(14)18-10-19(28-22(25)27-18)20-13-31(30-29-20)12-16-7-5-9-21(26-16)23(2,3)32/h4-10,13,32H,12H2,1-3H3,(H2,25,27,28)

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

In human in vitro cell cultures, moDC differentiated in the presence of adenosine showed a decreased ability to stimulate IFN-γ secretion from allogenic CD4+ T-cells in a MLR. This suppression is significantly reversed by addition of AB928. Multiplexed gene expression profiling using NanoString identified a cassette of 39 genes that are regulated by adenosine during moDC differentiation. AB928 shows rescue of these gene expression changes.

In Vivo:

Concurrent treatment with AB928 and chemotherapy results in significantly reduced tumor volume in vivo using AT3-OVA tumors; Similar results are observed for the combination of AB928 and NSC 266046. AB928 is also capable of suppressing growth of B16-F10 tumors both as a single agent or in combination with α-PD-1 therapy. AB928 increases the antitumor immune response leading to suppressed tumor growth and increased immune cell infiltration in mouse syngeneic tumors.


  1. Preparation of azolopyrimidine for the treatment of cancer and immune related disorders By Beatty, Joel; Debien, Laurent; Jeffrey, Jenna; Leleti, Manmohan Reddy; Mandal, Debashis; Miles, Dillon; Powers, Jay; Rosen, Brandon; Thomas-Tran, Rhiannon; Sharif, Ehesan. From PCT Int. Appl. (2018), WO 2018136700 A1 20180726.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed